A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Recruiting
Observational Study
Idiopathic Pulmonary Fibrosis (IPF)
Progressive Pulmonary Fibrosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30 (estimated)
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
* Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)
* Subject aged \> 18 years
* Able to willingly give consent
Exclusion Criteria:
* Co-morbidities currently requiring …
Contacts